Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30675584 | 1.00 | PIK3CD (0.40) | PIK3CDUHRF1ALDH1A1KDM4EPOLB | |
| SCHEMBL3183549 | 0.85 | PIK3CD (0.41) | PIK3CDUHRF1ALDH1A1KDM4EPOLB | |
| SCHEMBL11666508 | 0.80 | PIK3CD (0.43) | PIK3CDALDH1A1KDM4EPOLBSMN1; SMN2 | |
| SCHEMBL20687576 | 0.76 | PIK3CD (0.32) | PIK3CD | |
| SCHEMBL20679540 | 0.73 | ALDH1A1 (0.37) | ALDH1A1KDM4E | |
| SCHEMBL24533909 | 0.72 | ERBB2 (0.36) | ALDH1A1KDM4EPOLB | |
| SCHEMBL3190363 | 0.72 | UHRF1 (0.42) | UHRF1KDM4E | |
| SCHEMBL13480742 | 0.71 | CCR1 (0.38) | PIK3CDALDH1A1KDM4EPOLB | |
| SCHEMBL125275 | 0.71 | PIK3CD (0.51) | PIK3CDUHRF1ALDH1A1KDM4EPOLB | |
| SCHEMBL28008250 | 0.71 | HTT (0.38) | UHRF1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111615388-B | Immunotherapeutic agent for cancer | 斯汀格瑞治疗股份有限公司 | 2023-11-14 | — | — | CN | disclosed |
| EP-3658138-B1 | SUBSTITUTED-3H-IMIDAZO(4,5-C)PYRIDINE AND 1H-PYRROLO(2,3-C)PYRIDINE SERIES OF NOVEL ECTONUCLEOTIDE PYROPHSPHATASE/PHOSPHODIESTRASE-1 (ENPP1) AND STIMULATOR FOR INTERFERON GENES (STING) MODULATOR AS CANCER IMMUNOTHERAPEUTICS | STINGRAY THERAPEUTICS INC (US) | 2023-04-19 | — | — | EP | disclosed |
| US-11142524-B2 | Substituted-3H-imidazo[4,5-c]pyridine and 1H-pyrrolo[2,3-c]pyridine series of novel Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1) and stimulator for interferon genes (STING) modulators as cancer immunotherapeutics | Stingray Therapeutics, Inc. (US) | 2021-10-12 | — | — | US | disclosed |
| US-11142524-B2 | Substituted-3H-imidazo[4,5-c]pyridine and 1H-pyrrolo[2,3-c]pyridine series of novel Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1) and stimulator for interferon genes (STING) modulators as cancer immunotherapeutics | Stingray Therapeutics, Inc. (US) | 2021-10-12 | — | — | US | disclosed |
| CN-112996496-A | substituted-3H-imidazo [4,5-c ] pyridines and 1H-pyrrolo [2,3-c ] pyridines as novel ectonucleotide pyrophosphatase/phosphodiesterase-1 (ENPP1) and interferon gene Stimulator (STING) modulators for cancer immunotherapy | 斯汀格瑞治疗股份有限公司 | 2021-06-18 | — | — | CN | disclosed |
| EP-3829561-A1 | SUBSTITUTED-3H-IMIDAZO[4,5-C]PYRIDINE AND 1H PYRROLO[2,3-C]PYRIDINE SERIES OF NOVEL ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE-1 (ENPP1) AND STIMULATOR FOR INTERFERON GENES (STING) MODULATORS AS CANCER IMMUNOTHERAPEUTICS | Stingray Therapeutics, Inc. (US) | 2021-06-09 | — | — | EP | disclosed |
| CN-111615388-A | Novel ectonucleotide pyrophosphatase/phosphodiesterase-1 (ENPP1) and interferon gene Stimulator (STING) modulators of substituted-3H-imidazo [4,5-c ] pyridines and 1H-pyrrolo [2,3-c ] pyridines series as cancer immunotherapeutic agents | 斯汀格瑞治疗股份有限公司 | 2020-09-01 | — | — | CN | disclosed |
| US-10689376-B2 | Substituted-3H-imidazo [4,5-c] pyridine and 1H-pyrrolo[2,3-c]pyridine series of novel ectonucleotide pyrophosphatase/phosphodiesterase-1 (ENPP1) and stimulator for interferon genes (STING) modulators as cancer immunotherapeutics | Stingray Therapeutics, Inc. (US) | 2020-06-23 | — | — | US | disclosed |
| US-10689376-B2 | Substituted-3H-imidazo [4,5-c] pyridine and 1H-pyrrolo[2,3-c]pyridine series of novel ectonucleotide pyrophosphatase/phosphodiesterase-1 (ENPP1) and stimulator for interferon genes (STING) modulators as cancer immunotherapeutics | Stingray Therapeutics, Inc. (US) | 2020-06-23 | — | — | US | disclosed |
| US-20200039979-A1 | Substituted-3H-imidazo[4,5-c]pyridine and 1H-pyrrolo[2,3-c]pyridine series of novel Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1) and Stimulator for Interferon Genes (STING) modulators as cancer immunotherapeutics | Stingray Therapeutics, Inc. | 2020-02-06 | — | — | US | disclosed |
| US-20200039979-A1 | Substituted-3H-imidazo[4,5-c]pyridine and 1H-pyrrolo[2,3-c]pyridine series of novel Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1) and Stimulator for Interferon Genes (STING) modulators as cancer immunotherapeutics | Stingray Therapeutics, Inc. | 2020-02-06 | — | — | US | disclosed |
| WO-2020028724-A1 | SUBSTITUTED-3H-IMIDAZO[4,5-C]PYRIDINE AND 1H-PYRROLO[2,3-C]PYRIDINE SERIES OF NOVEL ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE-1 (ENPP1) AND STIMULATOR FOR INTERFERON GENES (STING) MODULATORS AS CANCER IMMUNOTHERAPEUTICS | Stingray Therapeutics, Inc. (US) | 2020-02-06 | — | — | WO | disclosed |
| WO-2020028724-A1 | SUBSTITUTED-3H-IMIDAZO[4,5-C]PYRIDINE AND 1H-PYRROLO[2,3-C]PYRIDINE SERIES OF NOVEL ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE-1 (ENPP1) AND STIMULATOR FOR INTERFERON GENES (STING) MODULATORS AS CANCER IMMUNOTHERAPEUTICS | Stingray Therapeutics, Inc. (US) | 2020-02-06 | — | — | WO | disclosed |
| US-20190031655-A1 | Substituted-3H-imidazo[4,5-c]pyridine and 1H-pyrrolo[2,3-c]pyridine series of novel Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1) and Stimulator for Interferon Genes (STING) modulators as cancer immunotherapeutics | Stingray Therapeutics, Inc. | 2019-01-31 | — | — | US | disclosed |
| US-20190031655-A1 | Substituted-3H-imidazo[4,5-c]pyridine and 1H-pyrrolo[2,3-c]pyridine series of novel Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1) and Stimulator for Interferon Genes (STING) modulators as cancer immunotherapeutics | Stingray Therapeutics, Inc. | 2019-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200039979-A1 | Substituted-3H-imidazo[4,5-c]pyridine and 1H-pyrrolo[2,3-c]pyridine series of novel Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1) and Stimulator for Interferon Genes (STING) modulators as cancer immunotherapeutics | STING1, ENPP1, CGAS | PIK3CD 139/4885UHRF1 2819/4885ALDH1A1 3527/4885 |
| US-20190031655-A1 | Substituted-3H-imidazo[4,5-c]pyridine and 1H-pyrrolo[2,3-c]pyridine series of novel Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1) and Stimulator for Interferon Genes (STING) modulators as cancer immunotherapeutics | STING1, ENPP1, CGAS | PIK3CD 139/4885UHRF1 2819/4885ALDH1A1 3527/4885 |
| US-11142524-B2 | Substituted-3H-imidazo[4,5-c]pyridine and 1H-pyrrolo[2,3-c]pyridine series of novel Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1) and stimulator for interferon genes (STING) modulators as cancer immunotherapeutics | STING1, ENPP1, CGAS | PIK3CD 139/4885UHRF1 2819/4885ALDH1A1 3527/4885 |
| US-10689376-B2 | Substituted-3H-imidazo [4,5-c] pyridine and 1H-pyrrolo[2,3-c]pyridine series of novel ectonucleotide pyrophosphatase/phosphodiesterase-1 (ENPP1) and stimulator for interferon genes (STING) modulators as cancer immunotherapeutics | STING1, ENPP1, CGAS | PIK3CD 139/4885UHRF1 2819/4885ALDH1A1 3527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.